Safety of Immune Checkpoint Inhibitors Prior to Liver Transplantation in Hepatocellular Carcinoma.
코호트
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
48 patients who received ICIs prior to LT (ICI cohort).
I · Intervention 중재 / 시술
ICIs prior to LT (ICI cohort)
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Our results demonstrate that rejection rates were similar in patients receiving ICIs pre-LT and it can be safely managed.
ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 44.0%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도
[BACKGROUND] Immune checkpoint inhibitors (ICIs) have emerged as promising agents for the management of advanced HCC.
- 표본수 (n) 48
- p-value p = 0.029
- p-value p = 0.027
- 연구 설계 cohort study
APA
Aceituno L, Magyar C, et al. (2026). Safety of Immune Checkpoint Inhibitors Prior to Liver Transplantation in Hepatocellular Carcinoma.. Alimentary pharmacology & therapeutics. https://doi.org/10.1111/apt.70528
MLA
Aceituno L, et al.. "Safety of Immune Checkpoint Inhibitors Prior to Liver Transplantation in Hepatocellular Carcinoma.." Alimentary pharmacology & therapeutics, 2026.
PMID
41640254 ↗
Abstract 한글 요약
[BACKGROUND] Immune checkpoint inhibitors (ICIs) have emerged as promising agents for the management of advanced HCC. By reducing tumour burden, ICIs may serve as a downstaging/bridging tool to improve transplant candidacy. The aim of this study was to assess the safety of patients receiving pre-LT ICIs.
[METHODS] Multicenter, retrospective cohort study from January 2018 to December 2024, including 48 patients who received ICIs prior to LT (ICI cohort). A control cohort (non-ICI cohort) was built (1:3) using propensity score matching including 144 patients who underwent LT for HCC without prior ICI.
[RESULTS] Within the ICI cohort (N = 48) rejection occurred in 9 patients (18.8%), all biopsy-proven, with a median onset of 31 days post-LT (12.0-182.0). The median washout period was 60 days (13-96). Patients experiencing rejection had shorter washout periods (p = 0.029). All rejection episodes were successfully managed; two were steroid-resistant, one requiring re-transplantation. There were no rejection-related deaths. Of the 5 patients with HCC recurrence, 60% received ICI for < 90 days (p = 0.027). Comparison between the ICI and non-ICI cohort revealed no significant differences in rejection rates (18.8% vs. 19.4%, p = 0.916), graft failure, HCC recurrence, or overall mortality. Overall survival (OS) did not differ between ICI and non-ICI patients (p = 0.625) or between those with and without rejection (p = 0.119). Rejection was not associated with increased mortality, with deaths primarily attributed to infection or HCC recurrence.
[CONCLUSION] Our results demonstrate that rejection rates were similar in patients receiving ICIs pre-LT and it can be safely managed.
[METHODS] Multicenter, retrospective cohort study from January 2018 to December 2024, including 48 patients who received ICIs prior to LT (ICI cohort). A control cohort (non-ICI cohort) was built (1:3) using propensity score matching including 144 patients who underwent LT for HCC without prior ICI.
[RESULTS] Within the ICI cohort (N = 48) rejection occurred in 9 patients (18.8%), all biopsy-proven, with a median onset of 31 days post-LT (12.0-182.0). The median washout period was 60 days (13-96). Patients experiencing rejection had shorter washout periods (p = 0.029). All rejection episodes were successfully managed; two were steroid-resistant, one requiring re-transplantation. There were no rejection-related deaths. Of the 5 patients with HCC recurrence, 60% received ICI for < 90 days (p = 0.027). Comparison between the ICI and non-ICI cohort revealed no significant differences in rejection rates (18.8% vs. 19.4%, p = 0.916), graft failure, HCC recurrence, or overall mortality. Overall survival (OS) did not differ between ICI and non-ICI patients (p = 0.625) or between those with and without rejection (p = 0.119). Rejection was not associated with increased mortality, with deaths primarily attributed to infection or HCC recurrence.
[CONCLUSION] Our results demonstrate that rejection rates were similar in patients receiving ICIs pre-LT and it can be safely managed.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (4)
- Perioperative immunotherapy to reduce recurrence in resectable hepatocellular carcinoma - lessons learned from the CARES-009 trial.
- Beyond rejection risk: Identifying ideal candidates for pretransplant immune checkpoint inhibitors for HCC.
- The ANTICIPATE-NASH Models Stratify Better the Risk of Clinical Events Than Histology in Metabolic Dysfunction-Associated Steatotic Liver Disease Patients With Advanced Chronic Liver Disease.
- Editorial: Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Prior to Liver Transplantation-Current Evidence and Future Directions. Authors' reply.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Raman Spectroscopic Signatures of Hepatic Carcinoma: Progress and Future Prospect.
- SLC2A1 tumour-associated macrophages spatially control CD8 T cell function and drive resistance to immunotherapy in non-small-cell lung cancer.
- Distribution of Immune Cells in Tumor Microenvironment Correlates With Checkpoint Inhibitor Response in Nasopharyngeal Carcinoma: A Multiregional Study.
- Heat Shock Protein 47 as a Novel Predictive and Diagnostic Biomarker for Thrombosis in Hepatocellular Carcinoma.
- Immune Checkpoint Inhibitors for Recurrent Hepatocellular Carcinoma After Liver Transplantation: Safety Under an Immunosuppression-Preserving Strategy.
- Crosstalk Between -Regulatory Elements and Metabolism Reprogramming in Hepatocellular Carcinoma.